. 2018 Jun 5;9:1200. doi: 10.3389/fimmu.2018.01200

Table 3.

Anti-cN-1A reactivity among systemic lupus erythematosus (SLE) and primary Sjögren’s syndrome (pSS) cohorts in former and current studies.

Cohort	Technique	Origin of samples	Disease	Number of patients	Anti-cN-1A positivity (%)
Herbert et al. (4)	ELISA with 3 synthetic peptides	The Netherlands	SLE	44	20
Herbert et al. (4)	ELISA with 3 synthetic peptides	The Netherlands	pSS	22	36

Kramp et al. (7)	ELISA with recombinant full-length protein^a	North American	SLE	33	6
Kramp et al. (7)	ELISA with recombinant full-length protein^a	North American	pSS	20	0

Lloyd et al. (6)	Immunoblotting against NT5C1A (full-length)-transfected and nontransfected HEK 293 cell lysates	USA	SLE	96	14
Lloyd et al. (6)		USA	pSS	44	23

Muro et al. (5)	ELISA with recombinant full-length protein	Japan	SLE	50	6
Muro et al. (5)	ELISA with recombinant full-length protein	Japan	pSS	50	4

Rietveld et al. (current study)	ELISA with recombinant full-length protein^a	Europe	SLE	252	10
Rietveld et al. (current study)	ELISA with recombinant full-length protein^a	Europe	pSS	193	12

^aThe same standardized ELISA was used in these studies.